These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7797244)

  • 1. Prognostic value of cytokine and soluble Fc gamma receptor assays in oncology.
    Tartour E; Pannetier C; Mathiot C; Teillaud JL; Sautès C; Kourilsky P; Fridman WH
    Immunol Lett; 1995 Jan; 44(2-3):145-8. PubMed ID: 7797244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS).
    Mathiot C; Mary JY; Tartour E; Facon T; Monconduit M; Grosbois B; Pollet JP; Michaux JL; Euller Ziegler L; Sautès C; Bataille R; Fridman WH
    Br J Haematol; 1996 Dec; 95(4):660-5. PubMed ID: 8982042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.
    Hoover RG; Lary C; Page R; Travis P; Owens R; Flick J; Kornbluth J; Barlogie B
    J Clin Invest; 1995 Jan; 95(1):241-7. PubMed ID: 7529259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums].
    Mathiot C; Grosbois B; Teillaud JL; Tartour E; Mosseri V; Euller-Ziegler L; Daragon A; Michaux JL; Facon T; Bernard JF
    Rev Med Interne; 1993; 14(10):960. PubMed ID: 8009056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
    Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
    Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.
    Tartour E; Blay JY; Dorval T; Escudier B; Mosseri V; Douillard JY; Deneux L; Gorin I; Negrier S; Mathiot C; Pouillart P; Fridman WH
    J Clin Oncol; 1996 May; 14(5):1697-703. PubMed ID: 8622090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy.
    Hansen BD; Schmidt H; von der Maase H; Sjoegren P; Agger R; Hokland M
    Acta Oncol; 2006; 45(4):400-5. PubMed ID: 16760175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
    Turesson I; Abildgaard N; Ahlgren T; Dahl I; Holmberg E; Hjorth M; Nielsen JL; Odén A; Seidel C; Waage A; Westin J; Wislöff F
    Br J Haematol; 1999 Sep; 106(4):1005-12. PubMed ID: 10520004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
    Lauerova L; Dusek L; Simickova M; Kocák I; Vagundová M; Zaloudík J; Kovarík J
    Neoplasma; 2002; 49(3):159-66. PubMed ID: 12098001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
    Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
    Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosis.
    Szegedi A; Czirják L; Unkeless JC; Boros P
    Acta Derm Venereol; 1996 Jan; 76(1):21-3. PubMed ID: 8721484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
    Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
    Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of soluble Fc gamma receptors II (sCD32) and III (sCD16) in patients with heparin-induced thrombocytopenia.
    Saffroy R; Bachelot-Loza C; Fridman WH; Aiach M; Teillaud JL; Rendu F
    Thromb Haemost; 1997 Aug; 78(2):970-1. PubMed ID: 9268212
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
    Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
    Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.